Your browser doesn't support javascript.
loading
Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation.
Zhu, Lin; Kuang, Xinwei; Zhang, Guanxiong; Liang, Long; Liu, Dandan; Hu, Bin; Xie, Zuozhong; Li, Hui; Liu, Hong; Ye, Mao; Chen, Xiang; Liu, Jing.
Afiliação
  • Zhu L; Department of Dermatology, Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Kuang X; Molecular Biology Research Center, Center for Medical Genetics, Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, Hunan, China.
  • Zhang G; Department of Dermatology, Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Liang L; Department of Dermatology, Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Liu D; Department of Research and Development, Beijing GAP Biotechnology Co., Ltd, Beijing, China.
  • Hu B; Department of Dermatology, Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Xie Z; Molecular Biology Research Center, Center for Medical Genetics, Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, Hunan, China.
  • Li H; Molecular Biology Research Center, Center for Medical Genetics, Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, Hunan, China.
  • Liu H; Molecular Biology Research Center, Center for Medical Genetics, Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, Hunan, China.
  • Ye M; Department of Dermatology, Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Chen X; Department of Dermatology, Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, Changsha, Hunan, China hongliu1014@csu.edu.cn lihuiscienc
  • Liu J; Molecular Biology Research Center, Center for Medical Genetics, Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, Hunan, China.
J Immunother Cancer ; 10(5)2022 05.
Article em En | MEDLINE | ID: mdl-35577504
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Albendazol / Antígeno B7-H1 / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Albendazol / Antígeno B7-H1 / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China